## 3 Results and Discussion
### Volatile Compounds
\begin{table}
\begin{tabular}{c c c c c c c c c} \hline  & \multicolumn{2}{c}{LRI \({}^{\bullet}\)} & \multicolumn{2}{c}{Identification \({}^{\bullet}\)} & \multicolumn{2}{c}{CT} & \multicolumn{2}{c}{NT} & \multicolumn{2}{c}{PT15} & \multicolumn{2}{c}{PT30} & \multicolumn{2}{c}{PT45} \\  & **Literature \({}^{\text{b}}\)** & **Calculated \({}^{\text{c}}\)** & & & & & & \\ \hline \multicolumn{10}{c}{**Cynzelines**} \\ \hline
2.5-Dimethyllyrazine & 1325 & 1314 & MS + LRI & ND & \(22.27\pm 7.51\) \({}^{\text{a}}\) & ND & \(14.22\pm 2.72\) \({}^{\text{b}}\) & \(14.25\pm 1.53\) \({}^{\text{b}}\) \\
2-Methyl-6-ethylpyrazine & 1393 & 1382 & MS + LRI & ND & \(8.80\pm 5.27\) \({}^{\text{a}}\) & \(3.48\pm 0.23\) \({}^{\text{b}}\) & \(3.89\pm 0.74\) \({}^{\text{b}}\) & \(8.88\pm 1.48\) \({}^{\text{a}}\) \\
2-3.5-Timethyllyrazine & 1408 & 1395 & MS + LRI & \(18.68\pm 4.23\) & \(18.89\pm 6.70\) & \(15.22\pm 2.26\) & \(12.87\pm 1.48\) & \(17.97\pm 2.42\) \\
2-Ethly-3-5.5 & & & & & & & \\ dimethylpyrazine & 1443 & 1458 & MS + LRI & \(8.09\pm 4.37\) \({}^{\text{b}}\) & \(13.40\pm 3.89\) \({}^{\text{a}}\) & \(10.15\pm 1.24\) \({}^{\text{a}}\) & \(6.24\pm 0.36\) \({}^{\text{b}}\) & \(9.49\pm 1.56\) \({}^{\text{b}}\) \\ \hline \multicolumn{10}{c}{**Acids**} \\ \hline Butanoic acid & 1625 & 1621 & MS + LRI & ND & \(7.63\pm 2.33\) \({}^{\text{b}}\) & \(13.94\pm 2.52\) \({}^{\text{a}}\) & ND & \(11.73\pm 1.42\) \({}^{\text{a}}\) \\ Hexanoic acid & 1850 & 1859 & MS + LRI & \(45.88\pm 15.17\) \({}^{\text{a}}\) & \(5.41\pm 1.51\) \({}^{\text{a}}\) & \(10.42\pm 1.40\) \({}^{\text{a}}\) & \(25.97\pm 6.43\) \({}^{\text{b}}\) & \(12.05\pm 1.32\) \({}^{\text{a}}\) \\ \multicolumn{10}{c}{**Others**} \\ \hline
2.5-Perulffuran & 1235 & 1228 & MS + LRI & \(103.49\pm 23.50\) \({}^{\text{a}}\) & ND & \(13.25\pm 3.65\) \({}^{\text{a}}\) & \(59.97\pm 7.54\) \({}^{\text{b}}\) & \(19.16\pm 1.07\) \({}^{\text{a}}\) \\ Butylrolactone & 1615 & 1606 & MS + LRI & \(4.74\pm 1.45\) \({}^{\text{a}}\) & \(3.96\pm 1.07\) \({}^{\text{b}}\) & \(5.11\pm 0.59\) \({}^{\text{a}}\) & \(2.92\pm 0.11\) \({}^{\text{b}}\) & \(4.58\pm 0.52\)\({}^{\text{b}}\) \\
2-Acetylpyrrole & 1972 & 1900 & MS + LRI & \(2.74\pm 0.59\) \({}^{\text{a}}\) & \(1.90\pm 0.60\) \({}^{\text{b}}\) & \(2.02\pm 0.22\) \({}^{\text{a}}\) & \(2.32\pm 0.14\) \({}^{\text{a}}\) & \(1.67\pm 0.17\) \({}^{\text{b}}\) \\ \hline \end{tabular} \({}^{\text{a,b,b}}\) Mean values in the same row followed by different letters are significantly different (\(p<0.05\)). \({}^{\text{a}}\) Linear retention index. \({}^{\text{b}}\) Reported data, \({}^{\text{c}}\) Calculated data based on n-alkanes (\(\text{C}_{\text{r}}\)-\(\text{C}_{\text{d}}\)). \({}^{\text{d}}\) Reliability of identification. We validate comparisons relatively longland by comparing their mass spectra with those contained in the MS library, LRI value compounds extensively identified by comparing their LRI with those reported in the literature, ND. Not detected, Control group (\(\text{C}_{\text{r}}\)), without sodium nitrite and plasma treatment, NT; with \(0.005\) sodium nitrite PT15 with plasma treatment for 15 min PT30, with plasma treatment for 30 min PT45, with plasma treatment for 45 min.  
\end{table} 
Table 3: _Cont._Figure 3A shows that in the CT samples, the volatile compounds with OAVs \(>\) 1 included eight kinds of aldehydes (hexanal, heptanal, octanal, nonanal, (E)-2-octenal, (E)-2-nonenal, decanal, and (E, E)-2,4-decadienal), three alcohols (1-octen-3-ol, (E)-2-octen-1-ol, and propyl disulfide), 2-ethyl-3,5-dimethylpyrazine, and 3-hydroxy-2-butanone. These 13 volatile compounds may be the main contributors for the flavour of the CT samples. As shown in Table 3, the contents of these 13 volatile compounds were affected by the nitrite and plasma treatment. In terms of nitrite treatment, the sample contained only two kinds of aldehydes (octanal and nonanal), three alcohols (1-octen-3-ol, (E)-2-octen-1-ol, and propyl disulfide), 2-ethyl-3,5-dimethylpyrazine, and 3-hydroxy-2-butanone.